Neuroblastoma (NB) is a highly complex and challenging pediatric cancer that affects the sympathetic nervous system, primarily occurring as a solid tumor in infants. Brain tumors are caused by the growth of abnormal cells in the brain. At Alfa Cytology, we are committed to helping our clients unravel the complexity of these diseases by providing integrated preclinical research solutions.
Introduction to Neuroblastoma
Neuroblastoma is rare, but it is recognized as the most prevalent solid tumor in infants, accounting for approximately 15% of all pediatric oncology deaths. It exhibits significant heterogeneity, ranging from spontaneous regression to the development of multi-focal and multi-drug-resistant disease. This complexity poses significant challenges in understanding the underlying biology of neuroblastoma and developing effective therapeutics.
Fig.1 Stage distribution of neuroblastoma patients aged <18 and ≥ 18 months at diagnosis. (Tas, M. L., et al., 2020)
Current Therapy Development for Neuroblastoma
| Therapies |
Mechanism of Action |
Current Drug Developmental Stage in NB |
| Hu14.18K322A |
Humanized mAb targeting GD2 |
Phase II trial for high-risk NB (NCT01857934) |
| Hu14.18-IL2 |
Humanized anti-GD2 mAb conjugated to IL-2 |
Completed phase II trial for r/r NB (NCT00082758) (NCT01334515) |
| GD2-targeting CAR-T |
T cells genetically modified to target GD2 |
Phase I/II trial for r/r NB (NCT03373097) (NCT02761915) |
| Alisertib (MLN8237) |
Aurora A kinase inhibitor |
Completed phase II trial for r/r NB (NCT01601535) |
| LY3295668 Erbumine |
Aurora A kinase inhibitor |
Phase I trial for r/r NB (NCT04106219) |
| Ceritinib |
Second-generation ALK inhibitor |
Phase II trial for high-risk NB (NCT02559778) (NCT01742286) |
| Lorlatinib |
Third-generation ALK inhibitor |
Phase III trial for high-risk NB (NCT03126916) |
| Idasanutlin |
Small-molecule antagonist of MDM2 |
Phase I/II trial for r/r NB (NCT04029688) |
| Perifosine |
AKT inhibitor |
Completed phase I trial for r/r NB (NCT00776867) |
| Temsirolimus |
mTOR inhibitor |
Phase II trial for r/r NB (NCT01767194) |
Our Services
At Alfa Cytology, our company develops biomarker assays and innovative therapeutics, including small molecule drugs, cell therapies, gene therapies, therapeutic antibodies, therapeutic peptides, and cancer vaccine to address the challenges posed by neuroblastoma. Through our ongoing research and development efforts, we are committed to helping pharmaceutical companies and researchers worldwide develop drugs and therapies to treat neuroblastoma.
We understand the critical role animal models play in advancing neuroblastoma research. We offer state-of-the-art animal model development services tailored specifically for neuroblastoma studies for our clients.
Animal Models
Xenograft Models
- Patient-Derived Xenograft (PDX) Model
- Cell Line Xenograft (CDX) Model
Genetically Engineered Mouse Models (GEMMs)
Cell Line Models
- Neuroblastic SH-SY5Y Cells
3D in Vitro Models
- Multicellular Tumor Spheroids
- Scaffold-Based Platforms
- Hydrogels
- Porous Scaffolds
Optional Species
- Mouse
- Rats
- Zebrafish
- Chick
- Non-human Primates
- Others
Ongoing research and advancements in understanding the biology of neuroblastoma continue to drive the development of novel therapeutic approaches. At Alfa Cytology, we are committed to providing comprehensive and cutting-edge solutions for the management of neuroblastoma. For more information about our comprehensive services, please don't hesitate to contact us.
Reference
- Tas, M. L., et al.; (2020). Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma. European journal of cancer, 124, 47-55.
For research use only.
Related Services
